Patents by Inventor Michel Perricaudet

Michel Perricaudet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant cells from the monocyte-macrophage cell line for gene therapy
    Patent number: 6210963
    Abstract: Cell compositions containing mononuclear phagocyte systems cells, and their use in cell therapy, e.g. adoptive immunotherapy, are disclosed.
    Type: Grant
    Filed: April 24, 1996
    Date of Patent: April 3, 2001
    Assignees: Institut National de la Sante et de la Recherche Medicale, Rhone-Poulenc Rorer S.A.
    Inventors: Hedi Haddada, Manuel Lopez, Michel Perricaudet
  • Defective recombinant adenoviruses with inactivated IVa2 gene
    Patent number: 6200798
    Abstract: The present invention relates to new viral vectors derived from adenoviruses, their preparation and utilization in gene therapy. It relates particularly to defective recombinant adenoviruses wherein the Iva2 gene at least is inactivated.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: March 13, 2001
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Patrice Yeh, Michel Perricaudet, Cécile Orsini, Emmanuelle Vigne
  • Replication deficient recombinant adenovirus vector
    Patent number: 6136594
    Abstract: The present invention relates to a replication deficient recombinant adenovirus vector in the genome of which is inserted an expression cassette comprising the DNA fragment coding for the human CFTR protein, said DNA fragment being placed under the control of the elements for the expression thereof.The present invention also concerns a vector according to claim 1 wherein in the expression cassette the human CFTR gene is under the control of the endogenous human CFTR promoter.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: October 24, 2000
    Assignee: Transgene S.A.
    Inventors: Wilfried Dalemans, Michel Perricaudet, Leslie Stratford-Perricaudet, Andrea Pavirani
  • Cells for the production of recombinant adenoviruses
    Patent number: 6127175
    Abstract: The invention relates to cells usable for the production of defective adenoviruses comprising, inserted into their genome, a portion of the region E4 of an adenovirus genome carrying the reading phase ORF6 under the control of a functional promoter.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: October 3, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Emmanuelle Vigne, Michel Perricaudet, Jean-Fran.cedilla.ois Dedieu, Cecile Orsini, Patrice Yeh, Martine Latta, Edouard Prost
  • Viral recombinant vectors for expression in muscle cells
    Patent number: 6099831
    Abstract: Non-replicatable viral recombinant vectors which are recognizable by muscle cell receptors, and furthermore modified by an insertion nucleic acid coding for a polypeptide sequence to be expressed in said muscle cells, are used to obtain a drug for treating muscle cell diseases or diseases which, by virtue of their location in the body, are accessible to the products of the expression of the above-mentioned nucleotide sequence, as secreted by said muscle cells. A method for producing said vectors, vectors such as those described above, and their use in pharmaceutical compositions are also provided.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 8, 2000
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Michel Perricaudet, Pascale Briand, Leslie Stratford-Perricaudet
  • Integrative recombinant adenoviruses, preparation thereof and therapeutical uses thereof
    Patent number: 6033885
    Abstract: The present invention relates to recombinant adenoviruses having a cassette capable of integrating into the genome of infected cells, their preparation, pharmaceutical compositions containing them, and their use. In particular, the cassette contains at least one inverted terminal repeat (ITR) Sequence from AAV and a heterologous DNA Sequence.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: March 7, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Martine Latta, Patrice Denefle, Emmanuelle Vigne, Michel Perricaudet
  • Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
    Patent number: 6013638
    Abstract: The present invention relates, in general, to a adenovirus mediated transfer of genes to the lung. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of desired genes to the lung whereby desired proteins of interest are produced for local and/or systemic use.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: January 11, 2000
    Assignees: The United States of America as represented by the Department of Health and Human Services, Transgene S.A.
    Inventors: Ronald G. Crystal, Wilfried Dalemans, Michel Perricaudet, Leslie Stratford-Perricaudet, Andrea Pavirani
  • Adenoviral vectors of canine origin
    Patent number: 5891715
    Abstract: The present invention resides in use of a recombinant adenovirus of animal origin containing a heterologous DNA sequence for the preparation of a pharmaceutical composition intended for the therapeutic and/or surgical treatment of the human body.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: April 6, 1999
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Hedi Haddada, Bernard Klonjkowski, Michel Perricaudet, Emmanuelle Vigne
  • Recombinant adero viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias
    Patent number: 5866551
    Abstract: The present invention concerns defective recombinant adenoviruses containing an inserted gene encoding apolipoproteins, pharmaceutical compositions comprising the adenovirus, and their use for the treatment or prevention of pathologies linked to dyslipoproteinemias.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: February 2, 1999
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Patrick Benoit, Patrice Denefle, Michel Perricaudet, Sandrine Seguret, Emmanuelle Vigne
  • Recombinant adenoviruses for gene therapy in cancers
    Patent number: 5837531
    Abstract: The invention concerns recombinant viruses comprising a heterologous DNA sequence under the control of expression signals specifically active in tumour cells, and their preparation and use in the treatment and prevention of cancers
    Type: Grant
    Filed: May 13, 1996
    Date of Patent: November 17, 1998
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jean-Fran.cedilla.ois Dedieu, Aude Le Roux, Michel Perricaudet
  • Method for preparing recombinant adeno-associated viruses (AAV), and uses thereof
    Patent number: 5789390
    Abstract: A novel method for preparing vectors derived from adeno-associated viruses (AAV), cells used therefor, and the use of the resulting vectors, particularly in gene and/or cell therapy, are disclosed.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: August 4, 1998
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Vincent Descamps, Michel Perricaudet